{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:13:42Z","timestamp":1791112422839,"version":"4.1.0"},"reference-count":48,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T00:00:00Z","timestamp":1206316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":["openaidsjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOAIDJ"],"published-print":{"date-parts":[[2008,3,24]]},"abstract":"<jats:sec>\n             <jats:title>Background:<\/jats:title>\n            <jats:p>There is increasing evidence that metabolic adverse effects associated with antiretroviral therapy may translate into an increased cardiovascular risk in HIV-1-infected patients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n             <jats:title>Objectives:<\/jats:title>\n        \n               <jats:p>To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-1-infected persons, and to investigate any association between them, stage of HIV-1 disease, and use of antiretroviral therapies.<\/jats:p>\n\t\t\t<\/jats:sec>               \n \t\t\t<jats:sec>\n             <jats:title>Methods:<\/jats:title>\n             <jats:p>Multicentric, cross-sectional analysis of CVD risk factors of treated patients in the VACH cohort. The data collected includes: demographic variables, cigarette smoking, diabetes mellitus, hypertension, dyslipidemia, body mass index, stage of HIV-1 infection, and antiretroviral therapy.<\/jats:p>\n             <\/jats:sec>   \n             <jats:sec>\n             <jats:title>Results:<\/jats:title>\n              <jats:p>The analysis included 2358 patients. More than 18% of the study population was at an age of appreciable risk of CVD. 1.7% had previous CVD and 59.2% were smokers. Increased prevalence of elevated total cholesterol was observed among subjects receiving an NNRTI but no PI [odds ratio (OR), 3.34; 95% confidence interval (CI), 1.77\u20136.31], PI but no NNRTI (OR, 4.04; 95% CI, 2.12\u20137.71), or NNRTI + PI (OR, 17.77; 95% CI, 7.24\u201343.59) compared to patients treated only with nucleoside reverse transcriptase inhibitors (NRTI). Higher CD4 cell count, lower plasma HIV-1 RNA levels, clinical signs of lipodystrophy, longer exposure times to NNRTI and PI, and older age were all also associated with elevated cholesterol levels. The use of lipid lowering agents was very low among our patients.<\/jats:p>\n\t\t\t<\/jats:sec>            \n \t\t\t<jats:sec>\n             <jats:title>Conclusion:<\/jats:title>\n   \t\t\t <jats:p>Patients in the VACH cohort present multiple known risk factors for CVD, and a very low rate of lipid lowering therapy use. NNRTI and\/or PI-based antiretroviral therapies are associated with the worst lipid profile. This is more frequent in older subjects with greater CD4 counts and controlled HIV-1 replication.<\/jats:p>\n              <\/jats:sec>","DOI":"10.2174\/1874613600802010026","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T08:42:48Z","timestamp":1207039368000},"page":"26-38","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort"],"prefix":"10.2174","volume":"02","author":[{"given":"Domingo","family":"Pere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suarez-Lozano","family":"Ignacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teira","family":"Ram\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lozano","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terr\u00f3n","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viciana","family":"Pompeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonz\u00e1lez","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galindo","family":"M\u0227 Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geijo","family":"Paloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vergara","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cos\u00edn","family":"Jaime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ribera","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roca","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garcia-Alcalde","family":"M\u0227 Luisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1nchez","family":"Trinitario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torres","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacalle","family":"Juan Ram\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrido","family":"Myriam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-199907090-00001","volume":"13","author":"Behrens G","year":"1999","unstructured":"Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. \n                Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease in-hibitors \n                AIDS  \n\n                1999; \n                13\n            \n                : F63-70.","journal-title":"AIDS"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"Carr A","year":"1998","unstructured":"Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. \n                A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors \n                AIDS  \n\n                1998; \n                12\n            \n                : F51-8.","journal-title":"AIDS"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.aids.0000222074.45372.00","volume":"20","author":"Crane HM","year":"2006","unstructured":"Crane HM, Van Rompaey SE, Kitahata MM. \n                Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy \n                AIDS  \n\n                2006; \n                20\n            \n                : 1019-26.","journal-title":"AIDS"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-200104130-00021","volume":"15","author":"Cattelan AM","year":"2001","unstructured":"Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. \n                Indinavir and systemic hypertension \n                AIDS  \n\n                2001; \n                15\n            \n                : 805-7.","journal-title":"AIDS"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00002030-200102160-00005","volume":"15","author":"Depairon M","year":"2001","unstructured":"Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. \n                Swiss HIV Cohort Study Premature atherosclerosis in HIV-infected individuals.Focus on protease inhibitor therapy \n                 AIDS  \n\n                2001; \n                15\n               \n                : 329-34.","journal-title":"AIDS"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1097\/00002030-200011100-00001","volume":"14","author":"Maggi P","year":"2000","unstructured":"Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. \n                Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors \n                AIDS  \n\n                2000; \n                14\n               \n                : F123-128.","journal-title":"AIDS"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0021-9150(01)00736-5","volume":"162","author":"Seminari E","year":"2002","unstructured":"Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, et al. \n                Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors \n                Atherosclerosis  \n\n                2002; \n                162\n              \n                : 433-8.","journal-title":"Atherosclerosis"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/01.CIR.104.3.257","volume":"104","author":"Stein JH","year":"2001","unstructured":"Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. \n                Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction \n                Circulation  \n\n                2001; \n                104\n                \n                : 57-62.","journal-title":"Circulation"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","volume":"17","author":"Mary-Krause M","year":"2003","unstructured":"Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. \n                Clinical Epidemiology Group from the French Hospital Database.Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men \n                 AIDS  \n\n                2003; \n                17\n               \n                : 2479-86.","journal-title":"AIDS"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","volume":"360","author":"Holmberg S","year":"2002","unstructured":"Holmberg S, Moorman A, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. \n                HIV Outpatient Study (HOPS) investigators.Protease Inhibitor and cardiovascular outcomes in patients with HIV-1 \n                 Lancet  \n\n                2002; \n                360\n               \n                : 1747-8.","journal-title":"Lancet"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.ahj.2005.07.030","volume":"15","author":"Sudano I","year":"2006","unstructured":"Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. \n                Cardiovascular disease in HIV infection \n                Am Heart J  \n\n                2006; \n                15\n            \n                : 1147-55.","journal-title":"Am Heart J"},{"key":"refR12","first-page":"347","author":"El Sadr W","year":"2005","unstructured":"El Sadr W, Reiss P, De Wit S, De Wit S, 'Arminio Monforte A, Thi\u00e9baut R, et al. \n            \n                Relationship between prolonged exposure to combination ART and myocardial infarction effect of sex age and lipid changes  \n                BostonUSA  \n                2005; \n               \n                347.","journal-title":"Boston.USA"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","volume":"17","author":"Friis-Moller N","unstructured":"Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, 'Arminio Monforte A. \n                DAD study group Cardiovascular disease risk factors in HIV patients association with antiretroviral therapy results from the D:A:D Study \n                AIDS  \n              \n                17\n              \n                : 1179-93.","journal-title":"AIDS"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1097\/00002030-200212060-00023","volume":"16","author":"Suarez-Lozano I","year":"2002","unstructured":"Suarez-Lozano I, Fajardo JM, Garrido M, Roca B, Garcia-Alcalde ML, Geijo P, et al. \n                Epidemiological trends of HIV infection in Spain preventative plans have to be oriented to new target populations Spanish VACH Cohort \n                AIDS   \n                2002; \n                16\n                \n                : 2496-9.","journal-title":"AIDS"},{"key":"refR15","first-page":"1","volume":"41","year":"1992","unstructured":"Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults \n                MMWR  \n                1992; \n                41\n                (RR-17\n                )\n                : 1-19.","journal-title":"MMWR"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"Wilson PW","year":"1998","unstructured":"Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. \n                Prediction of coronary heart disease using risk factor categories \n                Circulation  \n\n                1998; \n                97\n              \n                : 1837-47.","journal-title":"Circulation"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/bmj.319.7210.630","volume":"319","author":"Ramsay LE","year":"1999","unstructured":"Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. \n                British Hypertension Society Guidelines for Hypertension Management.Summary \n                 BMJ  \n\n                1999; \n                319\n            \n                : 630-5.","journal-title":"BMJ"},{"key":"refR18","unstructured":"Report of a WHO Consultation. \n                Obesity: Preventing and Managing the Global Epidemic.(2000) \n                World Health Organ Tech Rep Ser  \n                2000; \n                894\n                : I-253."},{"key":"refR19","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","volume":"269","year":"1993","unstructured":"Summary of the Second Report of the National Cholesterol Education Program NCEP Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel II \n                JAMA  \n               1993; \n                269\n                : 3015-23.","journal-title":"JAMA"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1468-1293.2006.00401.x","volume":"07","author":"Floris-Moore M","year":"2006","unstructured":"Floris-Moore M, Howard AA, Lo Y, Arnsten JH, Santero N, Schoenbaum EE. \n                Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women \n                HIV Med  \n\n                2006; \n                07\n            \n                : 421-30.","journal-title":"HIV Med"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"1351S","DOI":"10.1093\/ajcn\/61.6.1351S","volume":"61","author":"Serra-Majem L","year":"1995","unstructured":"Serra-Majem L, Ribas L, Tresserras R, Ngo J, Salleras L. \n                How could changes in diet explain changes in coronary heart disease mortality in Spain?.The Spanish paradox \n                 Am J Clin Nutr  \n\n                1995; \n                61\n                (6 Suppl)\n            \n                : 1351S-9S.","journal-title":"Am J Clin Nutr"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-145-1-200607040-00004","volume":"145","author":"Estruch R","year":"2006","unstructured":"Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI. \n                Effects of a Mediterranean-style diet on cardiovascular risk factors a randomized trial \n                Ann Intern Med  \n\n                2006; \n                145\n            \n                : 1-11.","journal-title":"Ann Intern Med"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","volume":"189","author":"Fontas E","year":"2004","unstructured":"Fontas E, van Leth F, Sabin CA, Friis-M\u00f8ller N, Rickenbach M, 'Arminio Monforte A, et al. \n                Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy are different antiretroviral drugs associated with different lipid profiles \n                J Infect Dis  \n\n                2004; \n                189\n            \n                : 1056-74.","journal-title":"J Infect Dis"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","volume":"358","author":"Fellay J","year":"2001","unstructured":"Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. \n                Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study \n                Lancet  \n\n                2001; \n                358\n            \n                : 1322-7.","journal-title":"Lancet"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","volume":"31","author":"Bernasconi E","year":"2002","unstructured":"Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, et al. \n                Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs The Swiss HIV Cohort Study \n                J Acquir Immune Defic Syndr  \n\n                2002; \n                31\n            \n                : 50-5.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0212-8241(05)74808-8","volume":"22","author":"RIZWAN M","year":"2005","unstructured":"RIZWAN M. \n                Sociedad Espa\u00f1ola de Hipertensi\u00f3n-Liga Espa\u00f1ola para la Lucha contra la Hipertensi\u00f3n Arterial SEH-LELHA Gu\u00eda espa\u00f1ola de hipertensi\u00f3n arterial  \n                Hipertensin  \n\n                2005; \n                22\n                (Suppl 2)\n            \n                : 1-84.","journal-title":"Hipertensin"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"Carr A","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. \n                Diagnosis prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy hyperlipidaemia and diabetes mellitus a cohort study \n                Lancet  \n\n                1999; \n                353\n            \n                : 2093-9.","journal-title":"Lancet"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","volume":"14","author":"Purnell JQ","year":"2000","unstructured":"Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. \n                Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects \n                AIDS  \n\n                2000; \n                14\n            \n                : 51-7.","journal-title":"AIDS"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042560-200107010-00003","volume":"27","author":"Ruiz L","year":"2001","unstructured":"Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, et al. \n                Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy.1-year prospective follow-up of a multicenter randomized controlled study \n                 J Acquir Immune Defic Syndr  \n\n                2001; \n                27\n            \n                : 229-36.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","volume":"349","author":"Martinez E","year":"2003","unstructured":"Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. \n                Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection \n                N Engl J Med  \n\n                2003; \n                349\n            \n                : 1036-46.","journal-title":"N Engl J Med"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","volume":"02","author":"Walli R","year":"1998","unstructured":"Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. \n                Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients \n                AIDS  \n\n                1998; \n                02\n            \n                : F167-73.","journal-title":"AIDS"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","volume":"100","author":"Periard D","year":"1999","unstructured":"Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. \n                Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors The Swiss HIV Cohort Study \n                Circulation  \n\n                1999; \n                100\n            \n                : 700-5.","journal-title":"Circulation"},{"key":"refR33","year":"2000","unstructured":"DuPont Pharmaceuticals \n                Sustiva Prescribing Information \n\n                2000.","journal-title":"Sustiva Prescribing Information"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1468-1293.2006.00400.x","volume":"07","author":"Glass TR","year":"2006","unstructured":"Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, et al. \n                Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time the Swiss HIV Cohort Study \n                HIV Med  \n\n                2006; \n                07\n            \n                : 404-10.","journal-title":"HIV Med"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/135965350300800306","volume":"08","author":"Domingo P","year":"2003","unstructured":"Domingo P, Sambeat MA, Perez A, Ordonez J, Rodriguez J, Vazquez G. \n                Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine role of physical activity as a protective factor \n                Antivir Ther  \n\n                2003; \n                08\n            \n                : 223-31.","journal-title":"Antivir Ther"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","volume":"15","author":"van der Valk M","year":"2001","unstructured":"van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. \n                Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile \n                AIDS  \n\n                2001; \n                15\n            \n                : 2407-14.","journal-title":"AIDS"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00042560-200201010-00003","volume":"29","author":"Galli M","year":"2002","unstructured":"Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, et al. \n                Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors \n                J Acquir Immune Defic Syndr  \n\n                2002; \n                29\n            \n                : 21-31.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2362.1994.tb02185.x","volume":"24","author":"Constans J","year":"1994","unstructured":"Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. \n                Plasma lipids in HIV-infected patients a prospective study in 95 patients \n                Eur J Clin Invest  \n                1994; \n                24\n            \n                : 416-20.","journal-title":"Eur J Clin Invest"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1258\/0956462011923507","volume":"12","author":"Vergis EN","year":"2001","unstructured":"Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. \n                Dyslipidemia in HIV-infected patients: association with adherence to potent antiretroviral therapy \n                Int J STD AIDS  \n\n                2001; \n                12\n            \n                : 463-8.","journal-title":"Int J STD AIDS"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1086\/496981","volume":"41","author":"Lo JC","year":"2005","unstructured":"Lo JC, Kazemi MR, Hsue PY, et al. \n                The relationship between nucleoside analogue treatment duration, insulin resistance and fasting arterialized lactate level in patients with HIV infection \n                Clin Infect Dis  \n\n                2005; \n                41\n            \n                : 1335-40.","journal-title":"Clin Infect Dis"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/00002030-200110190-00013","volume":"15","author":"Sattler FR","year":"2001","unstructured":"Sattler FR, Qian D, Louie S, et al. \n                Elevated blood pressure in subjects with lipodystrophy \n                AIDS  \n\n                2001; \n                15\n            \n                : 2001-10.","journal-title":"AIDS"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/135965350501000706","volume":"10","author":"Thiebaut R","year":"2005","unstructured":"Thiebaut R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, Monforte AD, et al. \n                Predictors of hypertension and changes of blood pressure in HIV-infected patients \n                Antivir Ther  \n\n                2005; \n                10\n            \n                : 811-23.","journal-title":"Antivir Ther"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"Grinspoon S","year":"2005","unstructured":"Grinspoon S, Carr A. \n                Cardiovascular risk and body-fat abnormalities in HIV-infected adults \n                N Engl J Med  \n\n                2005; \n                352\n            \n                : 48-62.","journal-title":"N Engl J Med"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dube MP","year":"2003","unstructured":"Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. \n                 Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group \n                Clin Infect Dis  \n\n                2003; \n                37\n            \n                : 613-27.","journal-title":"Clin Infect Dis"},{"key":"refR45","volume":"133","author":"Knobel H","year":"2006","unstructured":"Knobel H, Jeric\u00f3 C, Guelar A, et al. \n                Dislipemia asociada a lopinavir\/ritonavir impacto en el control desde una unidad espec\u00edfica \n                Enferm Infecc Microbiol Clin 24 (Espec Congr):  \n                2006; \n                133","journal-title":"Enferm Infecc Microbiol Clin. 24 (Espec Congr):"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","volume":"14","author":"Graham I","year":"2007","unstructured":"Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. \n                European guidelines on cardiovascular disease prevention in clinical practice Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice constituted by representatives of nine societies and by invited experts \n                Eur J Cardiovasc Prev Rehabil  \n\n                2007; \n                14 \n            (Suppl 2 )\n\n                : S1-113.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"refR47","unstructured":"Friis-M\u00f8ller N, Weber R, D'Arminio Monforte A, et al. \n                Exposure to HAART Is Associated with an Increased Risk of Myocardial Infarction: The D:A:D Study: 2006 \n                \n                 In: 13th Conference on Retroviruses and Opportunistic Infections; \n                Denver, USA. 2006; p. \n                127."},{"key":"refR48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","volume":"07","author":"Law MG","year":"2006","unstructured":"Law MG, Friis-M\u00f8ller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, et al. \n                The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the DAD Study \n                HIV Med  \n\n                2006; \n                07\n            \n                : 218.","journal-title":"HIV Med"}],"container-title":["The Open AIDS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openaidsjournal.com\/contents\/volumes\/V02\/TOAIDJ-2-26\/TOAIDJ-2-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openaidsjournal.com\/contents\/volumes\/V02\/TOAIDJ-2-26\/TOAIDJ-2-26.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openaidsjournal.com\/contents\/volumes\/V02\/TOAIDJ-2-26\/TOAIDJ-2-26.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:45:50Z","timestamp":1760611550000},"score":1,"resource":{"primary":{"URL":"https:\/\/openaidsjournal.com\/VOLUME\/02\/PAGE\/26\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,24]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3,24]]}},"alternative-id":["TOAIDJ-2-26"],"URL":"https:\/\/doi.org\/10.2174\/1874613600802010026","relation":{},"ISSN":["1874-6136"],"issn-type":[{"value":"1874-6136","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2008-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-01-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-02-4","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}